{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:19:09Z","timestamp":1788452349051,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clinre.2026.102829","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:34:42Z","timestamp":1776011682000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can peripheral blood eosinophils predict primary non-response to Infliximab therapy in pediatric Crohn\u2019s disease?"],"prefix":"10.1016","volume":"50","author":[{"given":"Quanhua","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2026.102829_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease. Article","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(16)30195-0","article-title":"Incidence and phenotype of inflammatory bowel disease from 13 countries in Asia-Pacific: results from the Asia-Pacific Crohn's and Colitis Epidemiologic Study 2011-2013. Meeting Abstract","volume":"150","author":"Ng","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2026.102829_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Article","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10080","key":"10.1016\/j.clinre.2026.102829_bib0004","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease. Review","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn's Disease in a population-based cohort. Article","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2026.102829_bib0006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn's Disease in population-based cohorts. Review","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102829_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pedneo.2019.12.008","article-title":"Pediatric Inflammatory Bowel Disease in Asia: epidemiology and natural history. Review","volume":"61","author":"Huang","year":"2020","journal-title":"Pediatr Neonatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Review","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinre.2026.102829_bib0009","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Article","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"issue":"9317","key":"10.1016\/j.clinre.2026.102829_bib0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Article","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2026.102829_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(11)60369-7","article-title":"Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's Disease in children. Meeting abstract","volume":"140","author":"Hyams","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Review","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102829_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14712598.2019.1564034","article-title":"Characteristics of biological therapy in pediatric patients with Crohn's disease. Review","volume":"19","author":"Tarnok","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.clinre.2026.102829_bib0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk. Review","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.clinre.2026.102829_bib0015","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjv156","article-title":"A matrix-based model predicts primary response to Infliximab in Crohn's Disease. Article","volume":"9","author":"Billiet","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.clinre.2026.102829_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","article-title":"Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. Article","volume":"6","author":"Sprakes","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.clinre.2026.102829_bib0017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Review","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinre.2026.102829_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy222.322","article-title":"Multi-alleles predict primary non-response to infliximab therapies in Crohn's disease: a simple and practicable model. Meeting abstract","volume":"13","author":"Tang","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinre.2026.102829_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy222.089","article-title":"ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing. Meeting Abstract","volume":"13","author":"Jung","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.clinre.2026.102829_bib0020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/17425255.2017.1377180","article-title":"Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Review","volume":"13","author":"Wong","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102829_bib0021","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease. Article","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.clinre.2026.102829_bib0022","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.4049\/jimmunol.181.10.7390","article-title":"Intestinal macrophage\/epithelial cell-derived CCL11\/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. Article","volume":"181","author":"Ahrens","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102829_bib0023","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1189\/jlb.0807513","article-title":"Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis. Article","volume":"84","author":"Lampinen","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/MPG.0000000000000957","article-title":"Prevalence of peripheral eosinophilia at diagnosis in children with inflammatory bowel disease. Article","volume":"62","author":"Sadi","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"10.1016\/j.clinre.2026.102829_bib0025","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/ajg.2017.402","article-title":"Peripheral eosinophilia in patients with inflammatory bowel disease defines an aggressive disease phenotype. Article","volume":"112","author":"Click","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102829_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(22)61889-4","article-title":"Longitudinal multi-omics analysis identifies early blood-based predictors of anti-tnf therapy response in inflammatory bowel disease. Meeting abstract","volume":"162","author":"Mishra","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2026.102829_bib0027","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Article","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0028","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Article","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.clinre.2026.102829_bib0029","article-title":"Role of eosinophils in intestinal inflammation and fibrosis in inflammatory bowel disease: an overlooked villain? Review","volume":"12","author":"Jacobs","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102829_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MOG.0b013e32835ab29a","article-title":"Eosinophils in infection and intestinal immunity. Review","volume":"29","author":"Hogan","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102829_bib0031","first-page":"1140","article-title":"Eosinophils in inflammatory bowel disease. Review. Inflamm bowel dis","volume":"25","author":"Filippone","year":"2019","journal-title":"July"},{"issue":"1","key":"10.1016\/j.clinre.2026.102829_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/children10010006","article-title":"The relationship between eosinophil density in the colonic mucosa and eosinophil blood count in children: a cross-sectional study. Article","volume":"10","author":"Brylak","year":"2023","journal-title":"Children"},{"issue":"27","key":"10.1016\/j.clinre.2026.102829_bib0033","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3748\/wjg.v25.i27.3503","article-title":"Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. Review","volume":"25","author":"Loktionov","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102829_bib0034","first-page":"10","article-title":"Peripheral blood eosinophilia at diagnosis of inflammatory bowel disease is associated with severe disease course: a nationwide study from the epi-IIRN cohort. Article","volume":"19","author":"Yerushalmy-Feler","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","article-title":"Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in-vivo. Note","volume":"182","author":"Collins","year":"1995","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.clinre.2026.102829_bib0036","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1084\/jem.182.6.1897","article-title":"Immunoreactivity for interleukin-3 and interleukin-5 and granulocyte-macrophage colony-stimulating factor of intestinal-mucosa in bronchial-asthma. Article","volume":"182","author":"Wallaert","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinre.2026.102829_bib0037","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12931-018-0968-8","article-title":"Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Article","volume":"20","author":"Sridhar","year":"2019","journal-title":"Respir Res"},{"issue":"429","key":"10.1016\/j.clinre.2026.102829_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/scitranslmed.aan0333","article-title":"Eosinophil depletion suppresses radiation-induced small intestinal fibrosis. Article","volume":"10","author":"Takemura","year":"2018","journal-title":"Sci Transl Med"},{"issue":"9584","key":"10.1016\/j.clinre.2026.102829_bib0039","first-page":"318","article-title":"Defective acute inflammation in Crohn's disease: a clinical investigation (vol 367, pg 668, 2007). Correction","volume":"370","author":"Marks","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0040","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/jpn3.70160","article-title":"Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease. Article","volume":"81","author":"Davidson","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.clinre.2026.102829_bib0041","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. Article","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.clinre.2026.102829_bib0042","article-title":"Clinical significance of novel neutrophil-based biomarkers in the diagnosis and prediction of response to Infliximab therapy in Crohn's Disease. Article","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102829_bib0043","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Article","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clinre.2026.102829_bib0044","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hocanalysis. Article","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinre.2026.102829_bib0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Review","volume":"9","author":"Kopylov","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"issue":"20","key":"10.1016\/j.clinre.2026.102829_bib0046","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1001\/jama.2013.4466","article-title":"Management of active Crohn Disease. Article","volume":"309","author":"Cheifetz","year":"2013","journal-title":"JAMA-J Am Med Assoc"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:40:28Z","timestamp":1788450028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2210740126000768"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102829","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can peripheral blood eosinophils predict primary non-response to Infliximab therapy in pediatric Crohn\u2019s disease?","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}